8 results
Objectives1. Reduction of defect size after MMS with a pre-treatment with imiquimod 5% cream2. Reduction of tumour size of large nodular facial BCC, after pre-treatment with imiquimod 5% cream.3. Improvement of cosmetic results.4. Histological…
To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
This study aims to investigate the sensitivity and specificity of the history and physical examination for the diagnosis of giant cell arteritis, compared with the superficial temporal artery biopsy, and get more insight into the positive and…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
Primary objective: To compare long-term efficacy of curettage prior to IMQ 5% cream (Aldara®) therapy versus standard surgical excision in primary nBCC.Secondary objective: To assess compliance, pain, cosmetic outcomes, patient satisfaction, patient…
The primary objective of this study is to investigate if shear-wave elastography and contrast-enhanced ultrasonography can identify those patients most suitable fir an intervention (surgery or endoscopic balloon dilation) and those patients that…